Therapy News and Research

RSS

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Cylene Pharmaceuticals, Inc. today announced the presentation of encouraging data from an ongoing Phase I dose-escalation trial of CX-4945 in patients with solid tumors at the 2011 American Society of Clinical Oncology (ASCO) annual meeting held on June 4-8 in Chicago, IL.

6 Jun 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Medizintechnik acquires BSD-2000/3D/MR integrated hyperthermia system

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that Dr. Sennewald Medizintechnik GmbH (Medizintechnik) has purchased BSD Medical's BSD-2000/3D/MR Hyperthermia System (BSD-2000/3D/MR).

6 Jun 2011

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced an expanded clinical focus to include an autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.

6 Jun 2011

FDA grants Pathway marketing clearance for JETSTREAM Navitus revascularization catheter for PVD

Pathway Medical Technologies, Inc, an innovator of endovascular treatments for peripheral vascular disease (PVD), announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM Navitus, an enhanced revascularization catheter for the treatment of PVD.

6 Jun 2011

Roper acquires Northern Digital

Roper Industries, Inc. today announced that it has completed the previously announced acquisition of Northern Digital, Inc., a leading provider of 3-D measurement technology for medical applications.

6 Jun 2011

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Emergent BioSolutions Inc. announced today that it has acquired from TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas.

6 Jun 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy.

6 Jun 2011

New gene therapy may cure Type 1 diabetes

An experimental cure for Type 1 diabetes has a nearly 80 percent success rate in curing diabetic mice. The results, to be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston, offer possible hope of curing a disease that affects 3 million Americans.

6 Jun 2011

New UH Seidman Cancer Center center to offer latest treatments and technology

University Hospitals (UH) Seidman Cancer Center, Northeast Ohio's first and only freestanding cancer hospital, opens to patients on June 6. The ten-story, 150-bed cancer hospital will house the latest cancer-fighting treatments and technology – all in a patient-centered, healing-focused environment.

6 Jun 2011

Global gene therapy market to reach $300 million by 2015

The global gene therapy market is expected to grow to over $300 million by 2015, according to a new report available on companiesandmarkets.com. The gene therapy market will grow further driven by the human genome project, the increasing incidence of cancer and other critical diseases.

6 Jun 2011

Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress

Chiasma, Inc., a privately held biopharma company, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic (PK) profile similar to that of subcutaneously injected octreotide acetate.

6 Jun 2011

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).

6 Jun 2011

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Estrogen therapy improves low bone density due to anorexia nervosa in teenage girls with the disease when given as a patch or as a low oral dose that is physiological.

6 Jun 2011

$Skin wrinkles may allow identification of fracture risk in early menopausal women$

Skin wrinkles may allow identification of fracture risk in early menopausal women

A news study finds that the worse a woman's skin wrinkles are during the first few years of menopause, the lower her bone density is. The results will be presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Men with prostate cancer are at higher risk of developing diabetes or diabetes risk factors if they receive androgen deprivation therapy (ADT) to block the production or action of male hormones that can fuel the growth of this cancer.

6 Jun 2011

Additional radiation treatment shows promise for breast cancer surgery patients

Additional radiation treatment improves disease free survival lessening the chance of cancer recurring in women with early breast cancer who have had breast conserving surgery (lumpectomy), interim results of a new study found.

6 Jun 2011

$Stem cell transplant may help promote bone fracture healing$

Stem cell transplant may help promote bone fracture healing

Researchers at the University of North Carolina at Chapel Hill School of Medicine have shown in an animal study that transplantation of adult stem cells enriched with a bone-regenerating hormone can help mend bone fractures that are not healing properly.

6 Jun 2011

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Cell Therapeutics, Inc. announced encouraging interim results of a phase II clinical study of OPAXIO combined with temozolomide and radiotherapy in patients with newly diagnosed high-grade malignant brain tumors.

6 Jun 2011

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.

6 Jun 2011

Therapy News and Research

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Medizintechnik acquires BSD-2000/3D/MR integrated hyperthermia system

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

FDA grants Pathway marketing clearance for JETSTREAM Navitus revascularization catheter for PVD

Roper acquires Northern Digital

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

New gene therapy may cure Type 1 diabetes

New UH Seidman Cancer Center center to offer latest treatments and technology

Global gene therapy market to reach $300 million by 2015

Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Skin wrinkles may allow identification of fracture risk in early menopausal women

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Additional radiation treatment shows promise for breast cancer surgery patients

Stem cell transplant may help promote bone fracture healing

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News